Clinical Trial Detail

NCT ID NCT03245489
Title Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Medical University of South Carolina
Indications

head and neck squamous cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.